Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Med., 18 August 2025

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 12 - 2025 | https://doi.org/10.3389/fmed.2025.1677216

Correction: Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—A clinical pilot study

This article is a correction to:

  1. Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) -a clinical pilot study

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Correction on
Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—A clinical pilot study

by Fluge, Ø., Rekeland, I. G., Sørland, K., Alme, K., Risa, K., Bruland, O., Tronstad, K. J., and Mella, O. (2025). Front. Med. 12:1607353. doi: 10.3389/fmed.2025.1607353

In the Introduction section, paragraph 7, the last sentence incorrectly stated:

However, although specific functional autoantibodies were elevated during acute COVID-19 infection (14), the number and magnitude of autoreactivities to the exoproteome were similar in individuals with or without LC (17), suggesting that the pattern of functional autoantibody responses, rather than single pathogenic autoantibodies, may be relevant.

The correct sentence should read:

However, although specific functional autoantibodies were elevated during acute COVID-19 infection (14), the number and magnitude of autoreactivities to the exoproteome were similar in individuals with or without ME/CFS (17), suggesting that the pattern of functional autoantibody responses, rather than single pathogenic autoantibodies, may be relevant.

The original version of this article has been updated.

Keywords: ME/CFS clinical trial, daratumumab, autoantibodies, plasma cell, feasibility, pathomechanism

Citation: Frontiers Production Office (2025) Correction: Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—A clinical pilot study. Front. Med. 12:1677216. doi: 10.3389/fmed.2025.1677216

Received: 31 July 2025; Accepted: 01 August 2025;
Published: 18 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.